Digital diabetes management company Glooko has acquired Paris-based DIABNEXT, a fellow diabetes care platform.

DIABNEXT's app tracks patient diabetes metrics, allowing providers to monitor that data and provide care remotely. Glooko said it will offer its own platform and DIABNEXT, rebranded as Glooko XT, for the French market.

"We are very pleased to welcome the DIABNEXT team to Glooko and especially excited to add their well-regarded product to Glooko's portfolio, along with their expertise in the diabetes community in France," Glooko CEO Russ Johannesson said in a statement. 

"The addition of DIABNEXT expands our offerings with a unique platform that can help us better customize the patient experience and improve health outcomes for people with diabetes. Glooko's acquisition of DIABNEXT further cements our commitment to increase our global presence and continue to drive innovative solutions."

This is Glooko's second acquisition this year. In January, the company announced it had purchased Berlin-based xbird, maker of AI-based diabetes care tools. The company raised $30 million in Series D funding last year. 

Papa, which offers in-home assistance for seniors or other vulnerable populations, announced Wednesday it's expanding into the employer market.

The startup said partnerships with employers will provide caregiving support for workers who have to assist elderly, chronically ill or disabled family members in addition to their paid work. 

"For employees, the impossible balancing act between one's work and family roles impacts them, their dependents, and ultimately their employer," Andrew Parker, founder and CEO of Papa, said in a statement.

"Papa has shown success with Medicare Advantage and Medicaid members in terms of reduced loneliness and improved health, and we believe there is tremendous opportunity to extend our model to flexible family care, for help when, where, and how it's most needed."

In late 2021, Papa scooped up $150 million in Series D funding.

Digital chronic-condition management company Lark Health is developing an AI-enabled platform for preventing and managing atherosclerotic cardiovascular disease (ASCVD) and coronary artery disease (CAD) in partnership with Roche Diagnostics.

The Lark Heart Health program, which is set to launch later this year, uses the principles of cognitive behavioral therapy to provide coaching around healthy behaviors and reducing stress. 

"Lark Heart Health will help those at high risk prevent and actively manage cardiovascular disease through personalized digital coaching," cofounder and CEO Julia Hu said in a statement. "By leveraging our AI technology, we can deliver meaningful and engaging care at an unprecedented scale, and this collaboration with Roche Diagnostics will support the expansion of our proven tech platform into one of the costliest chronic disease markets."